

From: Ward-Peralta, Cherie
Sent: Monday, August 17, 2015 5:20 PM
To: Fernandez, Alexander Maximilian (max_fernandez@baxter.com)
Subject: STN 125577 - Information Request - Please respond by August 24, 2015

Our Reference: BL 125577/0

Baxter Healthcare Corporation
Attention: Maximilian Fernandez, PhD
Sent by email

Dear Dr. Fernandez:

We are reviewing your December 19, 2014, biologics license application (BLA) for von Willebrand Factor (Recombinant). We determined that the following information is necessary to continue our review:

Shipping Validation and Stability Study (DHRR)

1. Please provide shipping validation and stability studies for rFurin.

Determination of Polysorbate 80 by (b) (4) (DBSQC)

2. In response to our previous IR (Question 3-a, sent on 23rd April 2015) in which we had requested linearity/accuracy data in the drug product matrix, you have provided the results obtained by testing (b) (4) sample. As per your manufacturing process description, (b) (4) does not represent the final container sample. Thus, your response does not address our previous IR. As requested in the previous IR, please provide appropriate linearity/accuracy data using the drug product, and demonstrate parallelism of results between the standard and samples by regression analysis.
3. As requested in the previous IR question (3-c, sent on 23rd April 2015), please re-evaluate range of the assay based on the revised accuracy, linearity and precision data obtained from representative drug product samples, and modify your validation report.
4. You have evaluated intermediate precision with (b) (4) sample, which constitutes an (b) (4) according to your manufacturing process description. Thus, your results do not demonstrate intermediate precision for your drug product. As requested in the previous IR, please provide data obtained with your drug product to demonstrate that the method's variability is acceptable.
5. Please provide data to show specificity of the method based on the analysis of representative product samples and matrix solution/formulation buffer that does not contain polysorbate 80 to demonstrate that your results are not affected by the product matrix.

6. You have studied robustness by testing polysorbate 80 standards. Please provide data obtained using representative final container samples which address the effect of deliberate variation of critical method parameters.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by August 24, 2015 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

The action due date for this file is December 19, 2015.

Very Respectfully,

Cherie Ward-Peralta, M.S.

Regulatory Project Manager
Office of Blood Research and Review
Center for Biologics Evaluation and Research
10903 New Hampshire Ave
WO-71- 7328
Silver Spring, MD 20993
Phone: 240-402-8447
Email: cherie.ward-peralta@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."